Differences in treatment between the two IgG4-RD groups
| Variable | PB group (x) | HN group (Y) | P |
| Initial steroid therapy | 73.3% (n=44) | 100% (n=14) | 0.031 |
| Second line therapy, at least one agent* Azathioprine MMF Methotrexate | 26.7% (n=16) 22% (n=13) 3.3% (n=2) 6.7% (n=4) | 71.4% (n=10) 21.4% (n=3) 42.9% (n=6) 35.7% (n=5) | 0.031 |
| RTX therapy (in cases diagnosed since 2016) | 3.4% (n=1/29) | 50% (n=6/12) | 0.001 |
*n=the number of times a second line agent was prescribed—some individuals had more than one second line agent.
HN, head and neck; PB, pancreatobiliary; RTX, Rituximab.